Znn3bq.jpeg
²é¿´: 39  |  »Ø¸´: 0

danyuneau

гæ (³õÈëÎÄ̳)

[ÈÎÎñ] ÂÛÎÄÑ¡¿¯×ż±±ÏÒµ£¡

ÏÖ½ð½±Àø 5 Ôª
Çë×ÐϸÔĶÁÖ÷ÌùÄÚÈÝ£¬¸ù¾ÝÒªÇóÍê³ÉÈÎÎñºó£¬Í¨¹ý»ØÌûµÄÐÎʽÀ´ÁìÈ¡Éͽð¡£

ÄÚÈÝ

±¾ÈËÒÑÍê³ÉÎÄÕµÄд×÷£¬µ«ÊÇÓÉÓÚ±ÏÒµÔÚ¼´£¬ÐèÒªÔÚÃ÷Äê3Ô·Ý֮ǰÄõ½accept£¬Ï£ÍûÓÐÈËÄܹ»¸ù¾ÝÏÂÊöÄÚÈݰïÃ¦ÍÆ¼ö½ÓÊÕ¼¸ÂʸߺÍÉó¸åÖÜÆÚ¶ÌµÄÎÄÕ£¬·Ç³£¸Ðл£¡
Vinpocetine has found wide application in the treatment of cerebral diseases, and it shows benefits especially in the treatment of stroke and epilepsy. However, it has the disadvantages of low bioavailability and cardiac toxicity. Studies have shown that vinpocetine derivatives with higher potency can be obtained through modification and screening. The aim of this study is to assess the pharmacodynamics of vinpocetine derivative VPK from such aspects as anti-cerebral ischemia, anti-epilepsy, inhibiting PDE1 and Na+ channel.
The changes in the volume of cerebral infarction were examined after pharmacotherapy by employing rat model of cerebral ischemia reperfusion injury. PTZ-kindled SD rat and cynomolgus macaque epilepsy models were used to detect the latency, counts and duration of epilepsy, and to study the pharmacodynamic actions of VPK in vivo; the inhibitory effects of VPK on PDE1 and Na+ channel were also detected and its pharmacodynamic actions in vitro on stroke and epilepsy were expounded at the molecular level.
With respect to its in vivo pharmacodynamic effects, VPK was significantly superior to vinpocetine and carbamazepine in inhibiting cerebral infarction caused by middle cerebral artery occlusion (MCAO), prolonging the latency of epilepsy, reducing the counts and duration of epilepsy, which showed dose-dependent effect. At the molecular level in vitro, the 50% inhibitory concentrations (IC50) of VPK and vinpocetine for PDE1 were 1.97 ¦ÌM and 17.4 ¦ÌM respectively, and IC50s for NaV1.1 were 0.013 ¦ÌM and 0.25 ¦ÌM respectively. The results above show that the pharmacodynamic effects of VPK are significantly superior to that of vinpocetine and carbamazepine.
VPK has higher potency than vinpocetine in the treatment of stroke and epilepsy, which suggests that it may become a new drug candidate which is more effective in the treatment of stroke and epilepsy.

» ²ÂÄãϲ»¶

ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû
Ïà¹Ø°æ¿éÌø×ª ÎÒÒª¶©ÔÄÂ¥Ö÷ danyuneau µÄÖ÷Ìâ¸üÐÂ
×î¾ßÈËÆøÈÈÌûÍÆ¼ö [²é¿´È«²¿] ×÷Õß »Ø/¿´ ×îºó·¢±í
[¿¼ÑÐ] 0703»¯Ñ§Çóµ÷¼Á +20 ²»ÖªÃûµÄСئ 2026-04-08 20/1000 2026-04-09 10:50 by Öí»á·É
[¿¼ÑÐ] 292Çóµ÷¼Á +4 ЦЦԬ 2026-04-09 4/200 2026-04-09 10:09 by ditto77778
[¿¼ÑÐ] 0703»¯Ñ§ +29 ÄÝÄÝninicgb 2026-04-04 32/1600 2026-04-08 22:50 by Öí»á·É
[¿¼ÑÐ] Ò»Ö¾Ô¸Ö£ÖÝ´óѧ085600Çóµ÷¼Á +21 ³ÔµÄ²»ÉÙ 2026-04-05 24/1200 2026-04-08 16:47 by sunhuadong
[¿¼ÑÐ] 298Çóµ÷¼Á +4 ²ÐºÉÐÂÁø 2026-04-07 4/200 2026-04-07 23:02 by lbsjt
[¿¼ÑÐ] 326Çóµ÷¼Á +5 9ahye 2026-04-02 6/300 2026-04-07 21:37 by lijunpoly
[¿¼ÑÐ] ×÷ÔÔ330µ÷¼Á +3 ÎÒÒªÉϺÃѧ 2026-04-02 4/200 2026-04-07 19:54 by biomichael
[¿¼ÑÐ] 277¹¤¿ÆÇóµ÷¼Á +10 1915668 2026-04-04 11/550 2026-04-06 23:53 by ÐÄæÂÒâ±±
[¿¼ÑÐ] ¿¼Ñе÷¼Á +7 15615482637 2026-04-04 7/350 2026-04-06 22:56 by chenzhimin
[¿¼ÑÐ] 338Çóµ÷¼Á +4 ÎÒÏëÉϰ¶ii 2026-04-05 4/200 2026-04-06 21:04 by ľ×Ó¾ý1218
[¿¼ÑÐ] Ò»Ö¾Ô¸Î人Àí¹¤´óѧ080200»úе¹¤³Ì308·Ö£¬Çóµ÷¼Á +4 ÖÕ²»ËÆ´Óǰ 2026-04-05 4/200 2026-04-06 11:46 by ¿¼ÑÐѧУÕеãÈË
[¿¼ÑÐ] 0855Çóµ÷¼Á²ÄÁÏ +11 ºìÌÒׯׯ 2026-04-04 12/600 2026-04-06 10:26 by À¶ÔÆË¼Óê
[¿¼ÑÐ] 085600£¬320·ÖÇóµ÷¼Á +16 ´ó²öС×Ó 2026-04-04 17/850 2026-04-06 07:58 by MOF_Catal
[¿¼ÑÐ] 0854Çóµ÷¼Á +4 assdll 2026-04-04 4/200 2026-04-05 09:44 by zhq0425
[¿¼ÑÐ] 341Çóµ÷¼Á +3 ѧÎÞÖ¹¾³£¬³å 2026-04-05 3/150 2026-04-05 09:40 by lbsjt
[¿¼ÑÐ] ¿¼Ñе÷¼Á +11 СsunÒªºÃÔË 2026-04-04 11/550 2026-04-05 08:02 by qlm5820
[¿¼ÑÐ] Äܶ¯µ÷¼Á326ר˶ +4 wan112233 2026-04-04 4/200 2026-04-04 22:47 by yu221
[¿¼ÑÐ] 22408£¬264Çóµ÷¼Á +3 ywh729 2026-04-03 4/200 2026-04-04 11:04 by ywh729
[¿¼ÑÐ] ±¾9Ò»Ö¾Ô¸2 0854µÍ·Öר˶286Çóµ÷¼Á +9 âÖÖ111 2026-04-04 9/450 2026-04-04 11:01 by tangruihua
[¿¼ÑÐ] ÉúÎïѧ308·ÖÇóµ÷¼Á£¨Ò»Ö¾Ô¸»ª¶«Ê¦´ó£© +7 ÏàÐűػá¹ââÍòÕ 2026-04-02 7/350 2026-04-03 16:48 by rzh123456
ÐÅÏ¢Ìáʾ
ÇëÌî´¦ÀíÒâ¼û